EA027148B1 - Способ лечения гиперхолестеринемии - Google Patents
Способ лечения гиперхолестеринемии Download PDFInfo
- Publication number
- EA027148B1 EA027148B1 EA201491545A EA201491545A EA027148B1 EA 027148 B1 EA027148 B1 EA 027148B1 EA 201491545 A EA201491545 A EA 201491545A EA 201491545 A EA201491545 A EA 201491545A EA 027148 B1 EA027148 B1 EA 027148B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- fat
- calebin
- diet
- kcal
- group
- Prior art date
Links
- 208000035150 Hypercholesterolemia Diseases 0.000 title claims abstract description 20
- 238000000034 method Methods 0.000 title claims abstract description 19
- 241000124008 Mammalia Species 0.000 claims abstract description 14
- 150000003626 triacylglycerols Chemical class 0.000 claims abstract description 9
- 210000002966 serum Anatomy 0.000 claims abstract description 7
- 208000006575 hypertriglyceridemia Diseases 0.000 claims abstract description 5
- 201000001320 Atherosclerosis Diseases 0.000 claims abstract 2
- 206010019708 Hepatic steatosis Diseases 0.000 claims abstract 2
- 206010033645 Pancreatitis Diseases 0.000 claims abstract 2
- UYEWRTKHKAVRDI-UHFFFAOYSA-N Calebin A Natural products C1=C(O)C(OC)=CC(C=CC(=O)COC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 UYEWRTKHKAVRDI-UHFFFAOYSA-N 0.000 abstract description 56
- UYEWRTKHKAVRDI-ASVGJQBISA-N Calebin A Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)COC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 UYEWRTKHKAVRDI-ASVGJQBISA-N 0.000 abstract description 56
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract description 48
- 108010010234 HDL Lipoproteins Proteins 0.000 abstract description 15
- 102000015779 HDL Lipoproteins Human genes 0.000 abstract description 15
- 108010007622 LDL Lipoproteins Proteins 0.000 abstract description 13
- 102000007330 LDL Lipoproteins Human genes 0.000 abstract description 13
- 230000000694 effects Effects 0.000 abstract description 11
- 108010062497 VLDL Lipoproteins Proteins 0.000 abstract description 10
- 210000004369 blood Anatomy 0.000 abstract description 10
- 239000008280 blood Substances 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 5
- 208000004930 Fatty Liver Diseases 0.000 abstract 1
- 208000010706 fatty liver disease Diseases 0.000 abstract 1
- 238000007726 management method Methods 0.000 abstract 1
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract 1
- 239000003925 fat Substances 0.000 description 92
- 235000019197 fats Nutrition 0.000 description 92
- 235000005911 diet Nutrition 0.000 description 43
- 230000037213 diet Effects 0.000 description 43
- 241001465754 Metazoa Species 0.000 description 40
- 235000009200 high fat diet Nutrition 0.000 description 23
- 235000012000 cholesterol Nutrition 0.000 description 21
- 208000008589 Obesity Diseases 0.000 description 11
- 230000007423 decrease Effects 0.000 description 11
- 235000020824 obesity Nutrition 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- 230000037396 body weight Effects 0.000 description 8
- 230000006698 induction Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 108010082126 Alanine transaminase Proteins 0.000 description 5
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 4
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 4
- 229930184164 Calebin Natural products 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 description 3
- 102000004895 Lipoproteins Human genes 0.000 description 3
- 108090001030 Lipoproteins Proteins 0.000 description 3
- 231100000460 acute oral toxicity Toxicity 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000003146 anticoagulant agent Substances 0.000 description 3
- 229940127219 anticoagulant drug Drugs 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 229910001220 stainless steel Inorganic materials 0.000 description 3
- 239000010935 stainless steel Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- QNAYBMKLOCPYGJ-UHFFFAOYSA-N Alanine Chemical compound CC([NH3+])C([O-])=O QNAYBMKLOCPYGJ-UHFFFAOYSA-N 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 108010088751 Albumins Proteins 0.000 description 2
- 208000024172 Cardiovascular disease Diseases 0.000 description 2
- 206010052895 Coronary artery insufficiency Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 238000008214 LDL Cholesterol Methods 0.000 description 2
- 208000007101 Muscle Cramp Diseases 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 210000004351 coronary vessel Anatomy 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000037023 motor activity Effects 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 206010013642 Drooling Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 206010020565 Hyperaemia Diseases 0.000 description 1
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000010428 Muscle Weakness Diseases 0.000 description 1
- 206010028372 Muscular weakness Diseases 0.000 description 1
- 206010065673 Nephritic syndrome Diseases 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 206010033546 Pallor Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000008630 Sialorrhea Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000004308 accommodation Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 210000003403 autonomic nervous system Anatomy 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 230000002566 clonic effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 235000020940 control diet Nutrition 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical class [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 229950010030 dl-alanine Drugs 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000010903 husk Substances 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037081 physical activity Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 238000001223 reverse osmosis Methods 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/25—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids with polyoxyalkylated alcohols, e.g. esters of polyethylene glycol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/259,404 US9668999B2 (en) | 2014-04-23 | 2014-04-23 | Method for the treatment of hypercholesterolemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201491545A1 EA201491545A1 (ru) | 2015-10-30 |
| EA027148B1 true EA027148B1 (ru) | 2017-06-30 |
Family
ID=50828681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201491545A EA027148B1 (ru) | 2014-04-23 | 2014-09-17 | Способ лечения гиперхолестеринемии |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US9668999B2 (enExample) |
| EP (1) | EP2937084B1 (enExample) |
| JP (1) | JP6263707B2 (enExample) |
| KR (1) | KR101647549B1 (enExample) |
| AU (1) | AU2014202312B2 (enExample) |
| CA (2) | CA2850999C (enExample) |
| EA (1) | EA027148B1 (enExample) |
| MY (1) | MY170067A (enExample) |
| PH (1) | PH12014000244A1 (enExample) |
| PL (1) | PL2937084T3 (enExample) |
| TW (1) | TWI622394B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201503805XA (en) * | 2015-04-19 | 2016-11-29 | Sabinsa Corp | Calebin A For Hepatic Steatosis |
| US9539232B1 (en) * | 2016-08-04 | 2017-01-10 | Muhammed Majeed | Calebin A for osteoporosis |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1156601A (zh) * | 1996-02-08 | 1997-08-13 | 袁克兴 | 降脂药及其制备方法 |
| CN101301455A (zh) * | 2008-07-01 | 2008-11-12 | 崔井朝 | 一种治疗高脂血症的中药复方姜黄固体分散体 |
| US20130195824A1 (en) * | 1998-04-01 | 2013-08-01 | Ganeden Biotech, Inc. | Methods for Reducing Cholesteron Using Bacillus Coagulans Spores, Systems and Compositions |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001030335A2 (en) * | 1999-10-22 | 2001-05-03 | The Board Of Trustees Of The University Of Illinois | Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease |
| US20020012733A1 (en) | 2000-04-12 | 2002-01-31 | The Procter & Gamble Company | Compositions for reducing hypercholesterolemia and controlling of postprandial blood glucose and insulin levels |
| JP2005232059A (ja) * | 2004-02-18 | 2005-09-02 | Iichiro Shimomura | 低アディポネクチン血症予防・治療剤 |
| JP4834824B2 (ja) * | 2004-07-08 | 2011-12-14 | 独立行政法人産業技術総合研究所 | アディポネクチン産生増強剤 |
| JP2010018522A (ja) * | 2007-03-23 | 2010-01-28 | Hiroshima Univ | アディポネクチン産生促進剤 |
| JP5294165B2 (ja) * | 2007-03-23 | 2013-09-18 | ナガセケムテックス株式会社 | アディポネクチン上昇剤 |
| JP2011063543A (ja) * | 2009-09-17 | 2011-03-31 | Kao Corp | アディポネクチン増加剤 |
| KR101702702B1 (ko) * | 2011-01-10 | 2017-02-03 | 무하메드 마제에드 | 칼레빈 ａ의 항-비만 가능성 |
-
2014
- 2014-04-23 US US14/259,404 patent/US9668999B2/en active Active
- 2014-04-29 AU AU2014202312A patent/AU2014202312B2/en not_active Ceased
- 2014-05-01 CA CA2850999A patent/CA2850999C/en active Active
- 2014-05-01 CA CA2963383A patent/CA2963383C/en active Active
- 2014-05-02 JP JP2014095457A patent/JP6263707B2/ja not_active Expired - Fee Related
- 2014-05-08 PL PL14167512T patent/PL2937084T3/pl unknown
- 2014-05-08 EP EP14167512.4A patent/EP2937084B1/en active Active
- 2014-06-10 KR KR1020140070179A patent/KR101647549B1/ko not_active Expired - Fee Related
- 2014-07-25 MY MYPI2014002207A patent/MY170067A/en unknown
- 2014-08-26 PH PH12014000244A patent/PH12014000244A1/en unknown
- 2014-09-03 TW TW103130375A patent/TWI622394B/zh not_active IP Right Cessation
- 2014-09-17 EA EA201491545A patent/EA027148B1/ru unknown
-
2015
- 2015-03-03 US US14/637,081 patent/US9610273B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1156601A (zh) * | 1996-02-08 | 1997-08-13 | 袁克兴 | 降脂药及其制备方法 |
| US20130195824A1 (en) * | 1998-04-01 | 2013-08-01 | Ganeden Biotech, Inc. | Methods for Reducing Cholesteron Using Bacillus Coagulans Spores, Systems and Compositions |
| CN101301455A (zh) * | 2008-07-01 | 2008-11-12 | 崔井朝 | 一种治疗高脂血症的中药复方姜黄固体分散体 |
Non-Patent Citations (2)
| Title |
|---|
| GUPTA Subash C. et al.: Multitargeting by turmeric, the golden spice: From kitchen to clinic. Mol. Nutr. Food Res., 2012, 00, p. 1-19 [онлайн][найдено 08.12.2014], Найдено в Интернете: <URL:http://onlinelibrary.wiley.com.scihub.org/doi/10.1002/mnfr.201100741/full> * |
| LI Yan et al.: Calebin-A induces apoptosis and modulates MAPK family activity in drug resistant human gastric cancer cells. European Journal of Pharmacology, 2008, 591(1-3), p. 252-258 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20150122552A (ko) | 2015-11-02 |
| US9610273B2 (en) | 2017-04-04 |
| CA2963383C (en) | 2018-12-04 |
| KR101647549B1 (ko) | 2016-08-10 |
| NZ624269A (en) | 2014-12-24 |
| TW201540295A (zh) | 2015-11-01 |
| MY170067A (en) | 2019-07-03 |
| CA2850999A1 (en) | 2015-10-23 |
| PH12014000244B1 (en) | 2016-08-08 |
| EA201491545A1 (ru) | 2015-10-30 |
| EP2937084A1 (en) | 2015-10-28 |
| JP2015209424A (ja) | 2015-11-24 |
| US9668999B2 (en) | 2017-06-06 |
| TWI622394B (zh) | 2018-05-01 |
| JP6263707B2 (ja) | 2018-01-24 |
| CA2963383A1 (en) | 2015-10-23 |
| AU2014202312B2 (en) | 2018-02-22 |
| CA2850999C (en) | 2018-04-03 |
| PH12014000244A1 (en) | 2016-08-08 |
| AU2014202312A1 (en) | 2015-11-12 |
| US20150306060A1 (en) | 2015-10-29 |
| PL2937084T3 (pl) | 2017-05-31 |
| US20150306059A1 (en) | 2015-10-29 |
| EP2937084B1 (en) | 2016-11-30 |
| HK1210590A1 (en) | 2016-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nishi et al. | Uremic sarcopenia: clinical evidence and basic experimental approach | |
| Sneddon | Clinical anesthesia and analgesia in fish | |
| Olanrewaju et al. | Interactive effects of photoperiod and light intensity on blood physiological and biochemical reactions of broilers grown to heavy weights | |
| Hoseini et al. | Serum biochemical characteristics of Beluga, Huso huso (L.), in response to blood sampling after clove powder solution exposure | |
| Wearing et al. | Phenotypic plasticity in the common snapping turtle (Chelydra serpentina): long-term physiological effects of chronic hypoxia during embryonic development | |
| Gerwick et al. | Modulation of stress hormones in rainbow trout by means of anesthesia, sensory deprivation and receptor blockade | |
| Zahl et al. | Anaesthesia of Atlantic halibut (Hippoglossus hippoglossus) Effect of pre‐anaesthetic sedation, and importance of body weight and water temperature | |
| Husmann et al. | Primary tumour growth in an orthotopic osteosarcoma mouse model is not influenced by analgesic treatment with buprenorphine and meloxicam | |
| Pipová Kokošová et al. | Melatonin mitigates hippocampal and cognitive impairments caused by prenatal irradiation | |
| EA027148B1 (ru) | Способ лечения гиперхолестеринемии | |
| TW202128162A (zh) | 憂鬱症之治療方法 | |
| Jones et al. | Evaluation of common anesthetic and analgesic techniques for tail biopsy in mice | |
| Chiba et al. | Comparison of the effects of chemical anesthesia and electroanesthesia on plasma cortisol levels in the Japanese eel Anguilla japonica. | |
| Rex et al. | Effects of repeated anesthesia containing urethane on tumor formation and health scores in male C57BL/6J mice | |
| Amari et al. | Comparison of Three Different Balanced Sedative-Anaesthetic Protocols in Captive Baboons (Papio hamadryas) | |
| PT1531839E (pt) | Feromonas calmantes de aves, para diminuir o stress, anxiedade e agressividade | |
| White | Early-Life Supplementation of Omega-3 Polyunsaturated Fatty Acids Improved Growth and Skeletal Muscle Glucose Metabolism in the Heat Stress-Induced IUGR Neonatal Lamb | |
| US8623914B2 (en) | Medical composition | |
| Munerato et al. | Physiologic effects of three different protocols of isoflurane anesthesia in captive brown brocket deer (Mazama gouazoubira) | |
| Tolmacheva et al. | Assessment of the sedative effect of various anesthetics in Coregonus Peled (Gmelin, 1789) in aquaculture | |
| Camenzuli | Effect of Acute Exercise on Muscle and Liver Glucose Metabolism in T1DM Rodents | |
| NZ624269B (en) | Method for the treatment of hypercholesterolemia | |
| HK1210590B (en) | Method for the treatment of hypercholesterolemia | |
| Maeda et al. | Effect of water temperature on the anesthetic effects of alfaxalone in carp (Cyprinus carpio) | |
| Zahl | Anaesthesia of farmed fish with special empasis on atlantic cod (Gadus morhua) and atlantic habibut (Hippoglossus hippoglossus) |